Graphene oxide (GO) and functionalized carbon nanotubes (f-CNTs) (each in the concentration range of 0.01–1.00 wt/wt%) were investigated as the reinforcing agent in a poly(methyl methacrylate) (PMMA)/hydroxyapatite (HA) bone cement. Mixed results were obtained for the changes in the mechanical properties determined (storage modulus, bending strength, and elastic modulus) for the reinforced cement relative to the unreinforced counterpart; that is, some property changes were increased while others were decreased. We postulate that this outcome is a consequence of the fact that each of the nanofillers hampered the polymerization process in the cement; specifically, the nanofiller acts as a scavenger of the radicals produced during polymerization reaction due to the delocalized π-bonds. Results obtained from the chemical structure and polymer chain size distribution determined, respectively, by nuclear magnetic resonance and size exclusion chromatography analysis, on the polymer extracted from the specimens support the postulated mechanism. Furthermore, in the case of the 0.5 wt/wt% GO-reinforced cement, we showed that when the concentration of the radical species in the PMMA bone cement was doubled, mechanical properties markedly improved (relative to the value in the unreinforced cement), suggesting suppression of the aforementioned scavenger activity.

Graphene and more specifically, nanographene oxide (GO) has been proposed as a highly efficient antitumoral therapy agent. Nevertheless, its cell uptake kinetics, its influence in different types of cells and the possibility of controlling cellular internalization timing, is still a field that remains unexplored. Herein, different cell types have been cultured in vitro for several incubation periods in the presence of 0.075 mg ml(-1) pegylated GO solutions. GO uptake kinetics revealed differences in the agent's uptake amount and speed as a function of the type of cell involved. Osteoblast-like cells GO uptake is higher and faster without resulting in greater cell membrane damage. Moreover, the dependence on the commonly used PEG nature (number of branches) also influences the viability and cell uptake speed. These facts play an important role in the future definition of timing parameters and selective cell uptake control in order to achieve an effective therapy.

This paper reviews recent advances in graphene-based biosensors development in order to obtain smaller and more portable devices with better performance for earlier cancer detection. In fact, the potential of Graphene for sensitive detection and chemical/biological free-label applications results from its exceptional physicochemical properties such as high electrical and thermal conductivity, aspect-ratio, optical transparency and remarkable mechanical and chemical stability. Herein we start by providing a general overview of the types of graphene and its derivatives, briefly describing the synthesis procedure and main properties. It follows the reference to different routes to engineer the graphene surface for sensing applications with organic biomolecules and nanoparticles for the development of advanced biosensing platforms able to detect/quantify the characteristic cancer biomolecules in biological fluids or overexpressed on cancerous cells surface with elevated sensitivity, selectivity and stability. We then describe the application of graphene in optical imaging methods such as photoluminescence and Raman imaging, electrochemical sensors for enzymatic biosensing, DNA sensing, and immunosensing. The bioquantification of cancer biomarkers and cells is finally discussed, particularly electrochemical methods such as voltammetry and amperometry which are generally adopted transducing techniques for the development of graphene based sensors for biosensing due to their simplicity, high sensitivity and low-cost. To close, we discuss the major challenges that graphene based biosensors must overcome in order to reach the necessary standards for the early detection of cancer biomarkers by providing reliable information about the patient disease stage.